Increased production of nitric oxide (NO) is thought to be a factor in the pathogenesis of many human diseases -among them the hypotension that often accompanies sepsis. The supply of the cationic amino acid arginine is known to be rate-limiting for NO production. We hypothesized that cationic amino acid transport might be increased in cells producing excess NO from patients with septic shock. Peripheral blood mononuclear cells were isolated from patients with sepsis and from healthy control subjects. The rates of both NO production and cationic amino acid uptake were increased in cells from patients with septic shock. The increased transport was due almost entirely to an increase in the activity of one transporter, subtype y + . The activity of the other major cationic amino acid transporter ( y + L) was unchanged. The expression of CAT2 mRNA, which encodes a y + transporter protein, was also increased in these cells. We suggest that CAT2 might be a therapeutic target to prevent excess NO production in sepsis and possibly other human disease states, while leaving basal production unchanged.
INTRODUCTION
Overproduction of nitric oxide (NO) is thought to be central to the pathogenesis of many diseases, among them septic shock. Septic shock is the leading cause of death in non-coronary intensive care, with a mortality rate of around 50 % [1] . While there is increasing evidence that the vasodilator NO is produced in increased quantities in septic shock [2] , endothelium-derived NO is now thought to be paradoxically reduced [3, 4] . The cellular source of this extra NO in sepsis is thus not known.
A decrease in NO production would be expected to improve the blood pressure of patients with septic shock, and presumably decrease mortality. The only known potent inhibitors of the NO biosynthetic pathway act Key words : arginine, CAT2, nitric oxide, sepsis, septic shock, y + , y + L.
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non-specifically on all NO synthase enzymes. While initial case reports using these drugs appeared promising [5, 6] , it now appears their therapeutic ratio is too narrow to be of clinical benefit. A number of other strategies to normalize NO production are under investigation. Among these, inhibition of the transport into the cell of the precursor to NO, L-arginine, may show particular promise.
The supply of arginine is known to be rate-limiting to the production of NO, in vitro [7] and in vivo [8] . Arginine enters mammalian cells through functionally distinct transport systems, principally systems y + and y + L [9] . Families of proteins with these functions have now been sequenced, and in humans are designated CAT1, CAT2 and CAT4 (encoding y + activity) and CD98 heavy chain combined with either y + LAT1 or y + LAT2 (encoding y + L activity). A recent study using macrophages from knockout mice [10] demonstrated that CAT2 accounted for 92 % of the increase in NO production and 95 % of the increase in arginine uptake when the cells were activated by interferon-γ and lipopolysaccharide. This suggests that CAT2 might be an attractive therapeutic target in attempts to limit excess NO production. However, it is clear that there are significant variations between species with regard to NO pathophysiology (as reviewed in [11] ), and whether CAT2 plays a similar role in clinical human disease is not known.
We therefore studied peripheral blood mononuclear cells (PBMCs) from patients with septic shock to determine if their NO production was increased. Furthermore, we investigated the functional and molecular changes in arginine transport that we hypothesized might be necessary to provide sufficient substrate for such an increase to occur.
METHODS

Patients
With ethics committee approval, we took blood samples from patients fitting the American College of Chest Physicians definition of septic shock [12] between 12 and 72 h from the time the inclusion criteria were first met. Consent was obtained from patients who were competent to give it, and whenever possible assent was asked of close relatives of patients unable to give consent (the Central Oxfordshire Research Ethics Committee does not require that specific consent is obtained for limited blood sampling for research when performed with simultaneous diagnostic sampling). Patients were excluded if they had a history of chronic inflammatory disease, or if they had received systemic corticosteroids in the preceding 6 months. Samples were also taken from healthy volunteer control subjects.
PBMC preparation
Blood was collected in heparinized (NO and transport assays) or EDTA [reverse transcription-PCR (RT-PCR) assay] tubes, diluted 1 : 1 (v\v) with an aerated Ringer's physiological salt solution, and layered over Ficoll\ sodium diatrizoate (LSM ; Cappel). After centrifugation at 240 g for 40 min, the PBMC layer was aspirated and washed with Ringer's solution. FACS analysis of PBMCs isolated in this manner showed that they were 15 % monocytes and 85 % lymphocytes. The PBMC concentration was determined by counting an aliquot of cells suspended in Trypan Blue in a haemocytometer. In the RT-PCR experiment, RNA concentration rather than cell count was used to standardize between subjects.
Nitric oxide production assay
Aliquots of 45 µl of a 10' cells\ml suspension of PBMCs were added to a clear 96-well plate, which contained the NO-specific dye 4,5-diaminofluorescein diacetate (DAF-2 DA) (Calbiochem) [13] at a final concentration of 10 µM, superoxide dismutase (Sigma) at a final concentration of 1000 units\ml and arginine at a final concentration of 30 µM (the lower end of the normal plasma arginine concentration range). DAF-2 DA enters cells freely, where it is esterified into DAF-2. As DAF-2 it cannot cross the cell membrane, and so the dye is concentrated inside the cells. In the presence of molecular oxygen, NO inside the cell reacts with DAF-2 to form DAF-2 T, a fluorescent product. The amount of DAF-2 T is proportional to the amount of NO within the cell. Cells from four of the patients with sepsis and four of the controls were also incubated with 10 mM of the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) in addition to arginine. The change in fluorescence after a 3.5 h incubation at 37 mC was recorded on a fluorescence plate reader using an excitation wavelength of 485 nm, and a detection wavelength of 535 nm. Control wells which contained DAF-2 DA and superoxide dismutase but no cells showed no increase in fluorescence over the time course of the assay, demonstrating the cell-dependence of the signal.
Cationic amino acid transport assay
The rate of influx of 2 µM $H-labelled L-lysine (80 Ci\ mmol ; Amersham) was measured at 37 mC under ' initial rate ' conditions over a time interval of 3 min. Lysine and arginine have indistinguishable transport kinetics [9] . Lysine was used rather than arginine as it is metabolically more stable once inside the cell. In contrast with lysine, arginine is a component of many active biochemical pathways, e.g. the urea cycle, and via transaminase to the tricarboxylic acid cycle, which causes transfer of the $H label to FADH # and eventually water. When the $H is transferred to a metabolite such as water, which leaves the cell, the measured rate of amino acid uptake is artifactually reduced. Labelled lysine is routinely used instead of arginine for this reason [9] . A 200 µl aliquot of the cell suspension was added to 700 µl of Ringer's solution containing radiolabelled L-lysine, or radiolabelled L-lysine plus 100 µM L-leucine. This allowed the relative contributions of systems y + and y + L to total transport to be determined, as system y + L is known to be almost completely cis-inhibited by this concentration of leucine. Aliquots (200 µl) of the cell\ amino acid mixture were removed at 15 s, 1, 2 and 3 min, layered over 50 µl of oil [dibutyl phthalate (Sigma)\ dinonyl phthalate (BDH), 3 : 2, v\v] in a 0.4 ml tube, and centrifuged for 10 s at 10 000 g. The tubes were then frozen and the bottom of each tube containing the cell pellet was cut off ; the radioactivity in this pellet was 
Real-time quantitative PCR assay
PBMCs isolated from 10 ml of blood were resuspended in 1.5 ml of a cell lysis solution containing citric acid, EDTA and SDS (Gentra), and stored at k80 mC. When sufficient samples had been accumulated, they were thawed on ice, and the remainder of the manufacturer's total RNA extraction protocol was completed. The samples were treated with DNase (DNA-free ; Ambion) to remove contaminating genomic DNA, and the concentration of RNA was calculated from its absorbance at 260 nm. After dilution to a standard concentration of 25 µg\ml, the RNA was reverse-transcribed using random hexamer primers and MultiScribe reverse transcriptase (TaqMan Gold RT reagent kit ; Applied Biosystems), using the manufacturer's recommended protocol. Segments of the cDNA produced were amplified using primers designed specifically for use in the TaqMan realtime PCR reaction, the concentration of which had been optimized in a preliminary experiment. In all cases, one of the primers (or the probe itself) crossed an intron\exon boundary, increasing the likelihood that only cDNA would be amplified. Each primer had been checked against all known mRNA sequences to ensure that it would bind only to the desired sequence. The sequences of the primers and probes used are shown in Table 1 .
The PCR mixture comprised a master mix of AmpliTaq Gold DNA polymerase, dNTPs, a passive reference fluorochrome and the necessary buffer (Applied Biosystems). The potential problem of contamination with product from previous PCR reactions was minimized by the use of heat-inactivated uracil-N-glycosylase in the PCR master mix, which contained dUTP rather than dTTP. The reaction was cycled according to the manufacturer's standard protocol. The quantity of PCR product was detected during and after each PCR cycle using an Applied Biosystems 7700 Sequence Detector.
Small variations in the starting quantity of cDNA in each sample were standardized by reference to the amplification of cDNA by primers and probe for the 18 S component of rRNA. PCR reactions identical to those described above were run for aliquots of each sample that had not been reverse transcribed. In all cases the quantity of product in these no-reverse transcription reactions was extremely small or non-existent. PCR reactions for cells from each subject were performed in quadruplicate. Amplification of the expected cDNA sequence was confirmed by agarose gel electrophoresis.
The starting quantity of cDNA in each sample is indicated by the number of cycles of PCR required to reach a threshold fluorescence intensity. For each sample, this was referred to the amplification of a serial dilution of human placenta cDNA (Clontech), a tissue known to express all of these mRNA species at high levels. The amount of each mRNA transcript present is thus expressed as a percentage of the expression of that mRNA in placenta.
RESULTS
Experimental subjects
The mean ages (with ranges) of the subjects were as follows : in the NO study : control subjects, 38.7 (22-56) years (n l 6) ; sepsis patients, 57.0 (17-77) years (n l 6) ; in the cationic amino acid transporter study : control, 37.2 (28-51) years (n l 6) ; sepsis, 63.3 (29-81) years (n l 7) ; for the mRNA study : control, 47.5 (30-58) years (n l 8) ; sepsis, 63 (43-76) years (n l 7). Patients with sepsis in the cationic amino acid transporter study and the mRNA study were statistically significantly older than the control subjects (P 0.02 in each case ; Student's t test). However, when the younger control subjects were excluded from the analyses presented below (such that there was no longer a significant difference in the ages of the two groups), the conclusions drawn were unchanged (i.e. the P value remained 0.05 for all previously identified differences, although in all cases P increased slightly, as the numbers of subjects in the control groups were less) (results for this age-based sub-analysis are not shown).
Nitric oxide production assay
PBMCs from sepsis patients produced more NO compared with those from control subjects (n l 6 in each group ; P 0.0004, Student's t test) (Figure 1 ). When 10 mM L-NAME was added to PBMCs as an extra experimental condition, this decreased the fluorescence of the PBMCs from the four sepsis patients (P 0.03) and four controls (P 0.05) studied, confirming that NO was responsible for the signal observed (results not shown).
Cationic amino acid transport assay
The total lysine uptake by PBMCs was almost doubled in cells from patients with sepsis : from a control rate of 1.88p0.76 pmol : min −" : 10' cells −" to 3.51p 1.17 pmol : min −" : 10' cells −" (n l 7 sepsis patients and n l 6 controls ; P 0.01, Student's t test) ( Figure  2 ). The increase in total transport was almost entirely due to an increase in y + transporter activity, which increased from 0.26p0.12 pmol : min −" : 10' cells −" in Figure 2 Total cationic amino acid influx, and amino acid influx due to the y + transporter, into PBMCs from seven sepsis patients and six healthy controls
Error bars represent the S.D. of total transport, and transport through the y + transporter.
PBMCs from controls to 1.78p0.90 pmol : min −" : 10' cells −" in cells from sepsis patients (P 0.002) (Figure 2) . When analysed as a proportion of the total transport, that due to the y + transporter had increased from 13.7p3.5 % of total transport in control PBMCs to 49.5p17.6 % in sepsis PBMCs (P 0.0005).
RT-PCR of arginine transporter mRNA
Each primer\probe combination produced detectable signal when the initial placental cDNA template was diluted to either 1-1 : 100 or 1 : 1000 (depending on the primer\probe in question). The only significant difference between PBMCs from control subjects and those with sepsis was an increase in CAT2 mRNA in sepsis ( Table 2) . No CAT2 mRNA was detected in any of the control PBMCs, while it was present in five of the seven samples from sepsis patients (P l 0.01, Fisher's exact test).
DISCUSSION
Plasma or tissue concentrations of NO metabolites are increased to a variable extent in many animal models of sepsis [14] [15] [16] [17] [18] [19] [20] , and this is usually taken as evidence of increased NO production. In patients with septic shock, after correcting for the confounding effects of renal dysfunction [2] , an increase in plasma NO metabolites is also detectable. Skeletal muscle from patients with sepsis had more inducible NO synthase mRNA, protein and activity than that from control patients [21] . Whether skeletal muscle is the main cellular source of the additional NO in human sepsis is not known, but evidence from animals suggests that circulating or marginated inflammatory cells such as PBMCs are also responsible, at least in part [22] [23] [24] [25] [26] . While a number of studies using human cells have shown up-regulation of the enzymes involved in NO synthesis, we have here for the first time directly demonstrated increased NO production by human cells in sepsis. These cells are themselves likely to be relevant in the pathogenesis of hypotension in sepsis, and may also reflect changes in other cell types, such as the vascular smooth muscle and adventitial fibroblasts. If a cell is producing more NO, it is possible that its membrane transport of arginine will be increased. There are many experimental systems in which increased arginine transport has been correlated with increased NO production. For example, murine macrophages [22] and rat vascular smooth muscle cells [27] are known to increase their arginine transport in concert with NO production when stimulated by lipopolysaccharide.
The present study of human PBMCs has shown a marked increase in arginine transport in cells from patients with septic shock. This is due predominantly to an increase in y + transporter activity, consistent with the observed increase in the mRNA encoding CAT2, a y + transporter protein. The molecular basis of similar changes in animal models is most consistently an increase in CAT2 mRNA [10, 23, 28, 29] , although many animal models also show a simultaneous increase in CAT1 [30] [31] [32] [33] . In that CAT1 mRNA levels were not changed in clinical human sepsis, the present study highlights the limitations of these animal models of human disease. The quantity of CAT2 mRNA detected in the PBMCs from sepsis patients appears small. The value reported may be low due to a relative abundance of CAT2 mRNA in the placental calibrator tissue : the absolute amount of CAT2 in placenta is not known. Even if the CAT2 mRNA level in these PBMCs is lower than that of the other transporter mRNAs, this does not necessarily correlate with its functional significance. What is certain is that these cells display increased y + transporter activity, and the increase in CAT2 was the only change observed at the mRNA level that could contribute to this. No antibody has been described to allow quantification of CAT2 protein, so whether this translates into raised protein levels cannot yet be determined. Indeed, no relationship of amino acid transporter mRNA to protein quantity and function has been described to date. However, the amounts of many other proteins are known to be poorly correlated with their mRNA level ; thus, even if the absolute amount of CAT2 mRNA in these cells is small, the amount of functional protein may be large.
In addition to protein amount, other factors with the potential to affect total y + transporter activity are the functional characteristics of the transporter and the membrane potential (as y + transport is electrogenic). The effects of sepsis on the functional properties of individual y + transporters and on membrane potential are not known.
Most importantly from a therapeutic point of view, the recent demonstration in cytokine-activated macrophages from knockout mice that CAT2 is required for almost all arginine transport and NO production [10] lends weight to the hope that inhibition of CAT2 in humans may lead to a successful treatment of septic shock.
Increased production of NO is thought to be important in the pathogenesis of diseases as diverse as ulcerative colitis, rheumatoid arthritis and chronic pain. Our result, which indicates that new expression of a single protein is likely to be responsible for the increased membrane transport of arginine that is required to upregulate NO production, thus has implications not only for septic shock, but also for the pharmacotherapy of other diseases. 
